Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs
Retrieved on:
Wednesday, June 21, 2023
Molecular biology, DNA, Paroxysmal extreme pain disorder, G protein-coupled receptor, Enzyme, Genomics, J&J, Chemistry, Protein, Investigational New Drug, Flagship Pioneering, Logic, Janssen Pharmaceuticals, Entrepreneurship, Cytokine, Health, Therapy, IND, Eurosport 1, Oncology, Pharmaceutical industry, Noubar Afeyan, Cole, Emperor
This approach systematically generates promising small molecule drug candidates at unprecedented speed.
Key Points:
- This approach systematically generates promising small molecule drug candidates at unprecedented speed.
- Founded by Flagship Pioneering, Empress generates good medicines, fast by starting with chemistry inside the human body.
- Flagship has made an initial commitment of $50 million to support the development of Empress's platform and the company's initial pipeline of drug candidates.
- In much the same way, we can now apply the programmability of the DNA code to create small molecule drugs predictably and quickly."